Eli Lilly and Company (NYSE:LLY)
- Net Inflows of from Institutional Investors in Dollars
- $66,208,814,337.00
- Net Inflows of from Institutional Investors in Shares
- 85,301,181
- Number of Institutional Transactions in the Last 90 Days
- 5,378
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
More about Eli Lilly and Company
